Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 5/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326722 | 0.79 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL23679750 | 0.76 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL10149677 | 0.76 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22349657 | 0.76 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21943279 | 0.76 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL15340435 | 0.76 | ACVRL1 (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL24075457 | 0.76 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL23476726 | 0.76 | ENPP1 (0.40) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21636967 | 0.76 | TLR7 (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21758936 | 0.74 | PI4KB (0.35) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | BEONE MEDICINES I GMBH (CH) | 2022-08-11 | — | — | US | disclosed |
| WO-2022127914-A1 | NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-23 | — | — | WO | disclosed |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3573718-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2021216572-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3854799-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020117624-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9242988-B2 | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160016980-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9090642-B2 | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2014059902-A1 | 2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012012465-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | CLARKE, MICHAEL, O'NEIL HANRAHAN (US) | 2012-01-26 | — | — | WO | disclosed |
| US-8012941-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | PI4KA 284/4885PI4K2B 580/4885PI4K2A 461/4885 |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | PI4KA 2603/4885PI4K2B 2247/4885PI4K2A 1649/4885 |
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NSUN2, RNGTT, NT5C3B | PI4KA 4427/4885PI4K2B 4034/4885PI4K2A 4318/4885 |
| US-20160016980-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PAICS, DPYD, PNP | PI4KA 787/4885PI4K2B 728/4885PI4K2A 961/4885 |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PAICS, DPYD, PNP | PI4KA 787/4885PI4K2B 728/4885PI4K2A 961/4885 |
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC28A2, SLC28A1, SLC29A2 | PI4KA 4438/4885PI4K2B 4172/4885PI4K2A 4217/4885 |
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | PI4KA 1132/4885PI4K2B 2299/4885PI4K2A 2099/4885 |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | CDA, PNP, MTAP | PI4KA 63/4885PI4K2B 162/4885PI4K2A 54/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | PI4KA 2603/4885PI4K2B 2890/4885PI4K2A 2680/4885 |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | STING1, CGAS, TLR9 | PI4KA 2504/4885PI4K2B 3068/4885PI4K2A 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.